Skip to main content
. 2016 Aug 9;7(37):60218–60229. doi: 10.18632/oncotarget.11130

Table 2. Analyses of outcomes by categories.

Outcome No. of studies Participants Statistical model Effect estimate (95% CI)
Stage I vs. II-IV 6 2315 Random-effects 0.84 (0.74, 0.96)
T1 vs. T2-4 11 26570 Random-effects 0.82 (0.77, 0.87)
N0 vs. N1-3 8 24763 Fixed-effect 0.85 (0.83, 0.87)
G2 vs. G1 8 1804 Fixed-effect 1.58 (1.40, 1.79)
G3 vs. G1 8 1542 Random-effects 2.17 (1.77, 2.67)
G3 vs. G2 8 2206 Random-effects 1.41 (1.25, 1.60)
ER vs. ER+ 12 117988 Random-effects 1.32 (1.22, 1.43)
Age < 50 vs. ≥ 50 years 8 27209 Random-effects 1.00 (0.91, 1.11)
Age < 40 vs. ≥ 40 years 3 1103 Fixed-effect 0.99 (0.81, 1.21)
Pre- vs. post-menopausal 4 1990 Random-effects 1.02 (0.93, 1.12)

CI, confidence interval.